XTX Topco Ltd Cuts Stake in Elanco Animal Health Incorporated (NYSE:ELAN)

XTX Topco Ltd cut its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 61.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,724 shares of the company's stock after selling 42,337 shares during the period. XTX Topco Ltd's holdings in Elanco Animal Health were worth $324,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. HighTower Advisors LLC lifted its stake in shares of Elanco Animal Health by 34.0% in the third quarter. HighTower Advisors LLC now owns 16,119 shares of the company's stock worth $237,000 after acquiring an additional 4,093 shares during the period. MML Investors Services LLC lifted its position in shares of Elanco Animal Health by 31.4% in the 3rd quarter. MML Investors Services LLC now owns 15,454 shares of the company's stock worth $227,000 after purchasing an additional 3,692 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Elanco Animal Health in the 3rd quarter valued at $35,000. Tidal Investments LLC raised its stake in Elanco Animal Health by 25.5% during the third quarter. Tidal Investments LLC now owns 84,578 shares of the company's stock worth $1,242,000 after buying an additional 17,206 shares during the last quarter. Finally, Franklin Resources Inc. lifted its holdings in Elanco Animal Health by 14.0% in the third quarter. Franklin Resources Inc. now owns 372,230 shares of the company's stock valued at $5,349,000 after buying an additional 45,795 shares during the period. 97.48% of the stock is owned by institutional investors.

Insider Transactions at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius bought 10,000 shares of the stock in a transaction dated Tuesday, March 11th. The stock was bought at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the acquisition, the director now directly owns 111,459 shares in the company, valued at approximately $1,136,881.80. This trade represents a 9.86 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.89% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Barclays lowered their price objective on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Piper Sandler dropped their price target on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, March 6th. Stifel Nicolaus reduced their price objective on shares of Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating for the company in a research report on Monday, April 14th. UBS Group dropped their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Finally, Morgan Stanley reduced their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $14.67.

Elanco Animal Health Stock Down 0.1 %

Shares of ELAN traded down $0.01 during trading hours on Friday, reaching $9.45. The stock had a trading volume of 4,397,166 shares, compared to its average volume of 4,932,984. The company has a market capitalization of $4.69 billion, a price-to-earnings ratio of 23.63, a P/E/G ratio of 2.50 and a beta of 1.44. The firm has a 50-day simple moving average of $10.03 and a 200 day simple moving average of $11.64. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $18.80.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the prior year, the business earned $0.08 earnings per share. The firm's quarterly revenue was down 1.4% compared to the same quarter last year. Equities research analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.